Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement - JSPR News | RalliesJasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement
J
JSPR• Initial Form 3 filing
- Jasper Therapeutics director Patrick J. Crutcher reported 518,331 voting common shares in an initial Form 3 filing dated July 16, 2026.
J
Johnson & Johnson names ChemT Biotechnology, Hill Research, Prima Mente, Waypoint Bio as QuickFire Challenge awardees, allocates USD 400,000 grants
JNJ•
